Comments
Alembic Pharmaceuticals Ltd today said it has entered into a drug development and licensing agreement with the US-based Accu-Break Pharmaceuticals under which it plans to launch over five generic drugs in the next two to three years.
Under the agreement, new brand of products will be developed using the technology of Accu-Break Pharmaceuticals (ABP) that makes it easier to split tablets by hand into accurate dosages, the firm said.
“Using this technology which makes it easier and safer for patients and caregivers to adjust dosage of tablets, we plan to launch five to six generic products in various therapeutic areas,” a senior company official said.
When asked by when the products would hit the market, the official said: “We are looking at a time frame of two to three years.”
The first product using Accu-Break technology that Alembic will seek USFDA marketing approval for is the popular anticoagulant medication warfarin, the official said.
“Our focus is mainly for the US market and so most of the products are intended for sale there. But we will also sell these in the domestic market,” the official said.
Shares of Alembic Pharmaceuticals were trading at Rs 65.25 per share in the afternoon trade on the BSE, up 2.59 per cent from the previous close.
Comments
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.